Anviro Therapeutics, founded in April 2015, is an early-stage biopharmaceutical company dedicated to developing broad-spectrum antiviral treatments for severe infectious diseases. Leveraging technology discovered by researchers at Brigham Young University (BYU), Anviro's core mission is to address unmet medical needs in the treatment of problematic viruses such as pox and herpes. Their lead compound, KPB-100, has demonstrated powerful antiviral properties and efficacy against a range of viruses within these families, particularly targeting acyclovir-resistant human herpes virus.

Notable affiliated individuals include researchers from BYU who discovered the foundational technology. Anviro has successfully licensed this technology and has made significant strides in validating KPB-100 as a potent antiviral solution. The company's work has the potential to significantly impact global health by providing effective treatments for viruses that pose substantial risks, especially to immunocompromised patients.